Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment.

Yang, CHCHYangChen, MCMCChenCheng, ALALChengHsu, CHCHHsuKun-Huei, YehYehKun-HueiYu, YCYCYuWhang-Peng, JJWhang-PengYang, PC.PC.Yang2010-09-032018-07-092010-09-032018-07-092005-07http://ntur.lib.ntu.edu.tw//handle/246246/196332en-US[SDGs]SDG3Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment.